Patents by Inventor Krzysztof Palczewski

Krzysztof Palczewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170196908
    Abstract: A method of treating diabetic retinopathy in a subject in need thereof includes administering to the subject a therapeutically effective amount of one or more agents that act as a trap of reactive aldehydes and/or inhibit diabetes-induced superoxide generation and capillary degeneration regulated by GPCR signaling pathways.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 13, 2017
    Inventors: Krzysztof Palczewski, Timothy Kern
  • Publication number: 20170112892
    Abstract: A pharmaceutical composition includes a retinylamine derivative having the following formula (I): where R1 is an amino acid residue, a dipeptide or a tripeptide that is linked to the retinylamine by an amide bond.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 27, 2017
    Inventors: Krzysztof Palczewski, Zheng-Rong Lu
  • Publication number: 20170014368
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Application
    Filed: July 19, 2016
    Publication date: January 19, 2017
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Publication number: 20160345827
    Abstract: A method of determining retinal degeneration of photoreceptors and/or the retinal pigment epithelium (RPE) of a subject includes measuring two-photon induced fluorescence inner and/or outer segments of the photoreceptor cells and/or retinal pigment epithelium to assess photoreceptor cell death and retinal pigment epithelium cell death or degeneration.
    Type: Application
    Filed: February 5, 2015
    Publication date: December 1, 2016
    Inventors: Krzysztof Palczewski, Grazyna Palczewski
  • Publication number: 20160331713
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 17, 2016
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Patent number: 9408821
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 9, 2016
    Assignee: University of Washington
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Patent number: 9403765
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 2, 2016
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Patent number: 9388130
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 12, 2016
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Publication number: 20160045453
    Abstract: Methods and compositions for stabilizing opsin protein, such as a Pro23His mutant opsin protein, in a vertebrate visual system, by administration of opsin-binding synthetic retinoids, are provided. The mutant opsin protein binds to the synthetic retinoid, which stabilizes the mutant opsin protein and/or ameliorates the effects of the mutant opsin protein on the vertebrate visual system.
    Type: Application
    Filed: September 4, 2015
    Publication date: February 18, 2016
    Inventors: Krzysztof Palczewski, Shalesh Kaushal, Vladimir Kuksa, Syed M. Noorwez
  • Patent number: 9233091
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: January 12, 2016
    Assignee: University of Washington
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Patent number: 9174936
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: November 3, 2015
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Patent number: 9169204
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 27, 2015
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Patent number: 9162978
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 20, 2015
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Patent number: 9149446
    Abstract: Methods and compositions for stabilizing opsin protein, such as a Pro23His mutant opsin protein, in a vertebrate visual system, by administration of opsin-binding synthetic retinoids, are provided. The mutant opsin protein binds to the synthetic retinoid, which stabilizes the mutant opsin protein and/or ameliorates the effects of the mutant opsin protein on the vertebrate visual system.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: October 6, 2015
    Assignees: UNIVERSITY OF WASHINGTON, REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Krzysztof Palczewski, Shalesh Kaushal, Vladimir Kuksa, Syed M. Noorwez
  • Patent number: 8962691
    Abstract: Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 24, 2015
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, David A. Saperstein
  • Publication number: 20140357611
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Krzysztof Palczewski, Akiko Maeda, Marcin Golczak
  • Patent number: 8889660
    Abstract: In one aspect of the present invention, a pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of (R)-all-trans-13,14-dihydroretinol and a pharmaceutically acceptable carrier or diluent. In another aspect of the present invention, pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of (S)-all-trans-13,14-dihydroretinol and a pharmaceutically acceptable carrier or diluent. In a further aspect of the present invention, a method is provided for treating a metabolic disease in a mammalian subject. The method includes administering to the subject a pharmaceutical composition comprising at least one all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: November 18, 2014
    Assignee: Case Western Reserve University
    Inventors: Krzysztof Palczewski, Radu Moise
  • Publication number: 20140330005
    Abstract: A composition includes a polysaccharide at least one retinoid linked to at least one monosaccharide subunit of the polysaccharide with a covalent linkage. The linkage being degradable by hydrolysis during digestion of the composition to provide controlled, delayed, and/or sustained delivery of the at least one retinoid upon enteral administration of the composition to a subject.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 6, 2014
    Inventors: Songqi Gao, Krzysztof Palczewski, Zheng-Rong Lu
  • Publication number: 20140235604
    Abstract: A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 21, 2014
    Inventors: Krzysztof Palczewski, Akiko Maeda, Marcin Golczak
  • Publication number: 20140235562
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Inventors: Krzysztof Palczewski, Yu Chen